| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 38, 2044-2054, Copyright © 1992 by American Association for Clinical Chemistry
RL Vessella, J Noteboom and PH Lange
Department of Urology, University of Washington Medical Center, Seattle 98195.
We detail the performance characteristics of the new IMx PSA immunoassay developed by Abbott Laboratories, addressing PSA recovery, assay reproducibility, standard curve storage, lower limit of detection, dilution linearity, and correlation with the Hybritech Tandem-R PSA immunoassay. We analyzed 686 sera for PSA retrospectively, testing 555 of these concurrently with the IMx and the Tandem-R immunoassays. The IMx PSA standard curve was linear from 0 to 100 micrograms/L, and curve storage was maintained for 4 weeks. The lower limit of detection of the IMx PSA assay was < or = 0.03 microgram/L; allowing for the assay precision yielded a biological detection limit of 0.06 microgram/L. We conservatively set the clinical threshold at 0.1 microgram/L. Regression analysis of dilution linearity involving 10 samples (0.44-200 micrograms/L) resulted in coefficients of correlation ranging from 0.9972 to 1.000. Reproducibility studies with 18 specimens within the range of 0.39-413.67 micrograms/L gave intra- and interassay CVs < 6.5%. The interassay 95% confidence interval for a specimen containing 0.06 microgram of PSA per liter was 0.03-0.09 microgram/L. Correlation between IMx and Tandem-R PSA assay results was excellent: r = 0.9909 and slope = 0.95. Overall, the IMx PSA immunoassay, with the conveniencies of automation, curve storage, and nonisotopic handling, provided an improved lower limit of PSA detection, which allows for earlier indication of residual or recurrent disease after radical prostatectomy.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  P. Stattin, S. Rinaldi, C. Biessy, U.-H. Stenman, G. Hallmans, and R. Kaaks High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened Cohort J. Clin. Oncol., August 1, 2004; 22(15): 3104 - 3112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stattin, A. Bylund, S. Rinaldi, C. Biessy, H. Dechaud, U.-H. Stenman, L. Egevad, E. Riboli, G. Hallmans, and R. Kaaks Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective Study J Natl Cancer Inst, December 6, 2000; 92(23): 1910 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nagasaki, M. Watanabe, N. Komatsu, T. Kaneko, J. Y. Dube, T. Kajita, Y. Saitoh, and Y. Ohta Epitope Analysis of a Prostate-specific Antigen (PSA) C-Terminal-specific Monoclonal Antibody and New Aspects for the Discrepancy between Equimolar and Skewed PSA Assays Clin. Chem., April 1, 1999; 45(4): 486 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Magnusson, L. Larsson, G. Englund, B. Larsson, P. Strang, and L. Selin-Sjogren Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain Clin. Chem., August 1, 1998; 44(8): 1621 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-F. Chen, Y. Xu, and M. P.-C. Ip Electrochemical Enzyme Immunoassay for Serum Prostate-Specific Antigen at Low Concentrations Clin. Chem., August 1, 1997; 43(8): 1459 - 1461. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
